5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Suicidality O
: O
Monitor O
for O
worsening O
of O
depressive O
symptoms O
and O
suicide O
risk O
( O
5.1 O
) O
. O

* O
Serotonin O
Syndrome O
: O
Serotonin O
syndrome O
has O
been O
reported O
with O
SSRIs O
and O
SNRIs O
, O
including O
Savella O
, O
both O
when O
taken O
alone O
, O
but O
especially O
when O
co-administered O
with O
other O
serotonergic O
agents O
( O
including O
triptans O
, O
tricyclic O
antidepressants O
, O
fentanyl O
, O
lithium O
, O
tramadol O
, O
tryptophan O
, O
buspirone O
and O
St O
. O
John O
's O
Wort O
) O
. O

If O
such O
symptoms O
occur O
, O
discontinue O
Savella O
and O
initiate O
supportive O
treatment O
. O

If O
concomitant O
use O
of O
Savella O
with O
other O
serotonergic O
drugs O
is O
clinically O
warranted O
, O
patients O
should O
be O
made O
aware O
of O
a O
potential O
increased O
risk O
for O
serotonin O
syndrome O
, O
particularly O
during O
treatment O
and O
dose O
increases O
( O
5.2 O
) O
. O

* O
Elevated O
blood O
pressure O
and O
heart O
rate O
: O
Savella O
may O
increase O
blood O
pressure O
and O
heart O
rate O
. O

In O
an O
ambulatory O
blood O
pressure O
monitoring O
study O
, O
a O
substantially O
higher O
proportion O
of O
Savella-treated O
patients O
experienced O
clinically O
significant O
blood O
pressure O
and O
heart O
rate O
elevations O
as O
compared O
with O
placebo-treated O
patients O
. O

Measure O
blood O
pressure O
and O
heart O
rate O
prior O
to O
initiating O
treatment O
with O
Savella O
and O
monitor O
periodically O
throughout O
treatment O
( O
5.3 O
, O
5.4 O
) O
. O

* O
Seizures O
: O
Cases O
have O
been O
reported O
with O
Savella O
therapy O
. O

Prescribe O
Savella O
with O
care O
in O
patients O
with O
a O
history O
of O
seizure O
disorder O
( O
5.5 O
) O
. O

* O
Hepatotoxicity O
: O
More O
patients O
treated O
with O
Savella O
than O
with O
placebo O
experienced O
mild O
elevations O
of O
ALT O
and O
AST O
. O

Rarely O
, O
fulminant O
hepatitis O
has O
been O
reported O
in O
patients O
treated O
with O
Savella O
. O

Avoid O
concomitant O
use O
of O
Savella O
in O
patients O
with O
substantial O
alcohol O
use O
or O
chronic O
liver O
disease O
( O
5.6 O
) O
. O

* O
Discontinuation O
: O
Withdrawal O
symptoms O
have O
been O
reported O
in O
patients O
when O
discontinuing O
treatment O
with O
Savella O
. O

A O
gradual O
dose O
reduction O
is O
recommended O
( O
5.7 O
) O
. O

* O
Abnormal O
Bleeding O
: O
Savella O
may O
increase O
the O
risk O
of O
bleeding O
events O
. O

Caution O
patients O
about O
the O
risk O
of O
bleeding O
associated O
with O
the O
concomitant O
use O
of O
Savella O
and O
NSAIDs O
, O
aspirin O
, O
or O
other O
drugs O
that O
affect O
coagulation O
( O
5.9 O
) O
. O

* O
Male O
patients O
with O
a O
history O
of O
obstructive O
uropathies O
may O
experience O
higher O
rates O
of O
genitourinary O
adverse O
events O
( O
5.11 O
) O
. O

5.1 O
Suicide O
Risk O
Savella O
is O
a O
selective O
serotonin O
and O
norepinephrine O
re-uptake O
inhibitor O
( O
SNRI O
) O
, O
similar O
to O
some O
drugs O
used O
for O
the O
treatment O
of O
depression B-Not_AE_Candidate
and O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
. O

Patients O
, O
both O
adult O
and O
pediatric O
, O
with O
depression B-Not_AE_Candidate
or O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
may O
experience O
worsening B-NonOSE_AE
of I-NonOSE_AE
their I-NonOSE_AE
depression I-NonOSE_AE
and/or O
the O
emergence O
of O
suicidal B-NonOSE_AE
ideation I-NonOSE_AE
and O
behavior O
( O
suicidality B-NonOSE_AE
) O
or O
unusual B-NonOSE_AE
changes I-NonOSE_AE
in I-NonOSE_AE
behavior I-NonOSE_AE
, O
whether O
or O
not O
they O
are O
taking O
these O
medications O
, O
and O
this O
risk O
may O
persist O
until O
significant O
remission O
occurs O
. O

Suicide B-NonOSE_AE
is O
a O
known O
risk O
of O
depression B-Not_AE_Candidate
and O
certain O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
, O
and O
these O
disorders O
themselves O
are O
the O
strongest O
predictors O
of O
suicide B-NonOSE_AE
. O

There O
has O
been O
a O
long-standing O
concern O
, O
however O
, O
that O
antidepressants O
, O
including O
drugs O
that O
inhibit O
the O
reuptake O
of O
norepinephrine O
and/or O
serotonin O
, O
may O
have O
a O
role O
in O
inducing O
worsening B-OSE_Labeled_AE
of I-OSE_Labeled_AE
depression I-OSE_Labeled_AE
and O
the O
emergence O
of O
suicidality B-OSE_Labeled_AE
in O
certain O
patients O
during O
the O
early O
phases O
of O
treatment O
. O

In O
the O
placebo-controlled O
clinical O
trials O
of O
adults O
with O
fibromyalgia B-Not_AE_Candidate
, O
among O
the O
patients O
who O
had O
a O
history O
of O
depression B-Not_AE_Candidate
at O
treatment O
initiation O
, O
the O
incidence O
of O
suicidal B-OSE_Labeled_AE
ideation I-OSE_Labeled_AE
was O
0.5 O
% O
in O
patients O
treated O
with O
placebo O
, O
0 O
% O
in O
patients O
treated O
with O
Savella O
100 O
mg/day O
, O
and O
1.3 O
% O
in O
patients O
treated O
with O
Savella O
200 O
mg/day O
. O

No O
suicides B-NonOSE_AE
occurred O
in O
the O
short-term O
or O
longer-term O
( O
up O
to O
1 O
year O
) O
fibromyalgia B-Not_AE_Candidate
trials O
. O

Pooled O
analyses O
of O
short-term O
placebo-controlled O
trials O
of O
drugs O
used O
to O
treat O
depression B-Not_AE_Candidate
( O
SSRIs O
and O
others O
) O
showed O
that O
these O
drugs O
increase O
the O
risk O
of O
suicidal B-OSE_Labeled_AE
thinking I-OSE_Labeled_AE
and O
behavior O
( O
suicidality B-OSE_Labeled_AE
) O
in O
children O
, O
adolescents O
, O
and O
young O
adults O
( O
ages O
18-24 O
) O
with O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
( I-Not_AE_Candidate
MDD I-Not_AE_Candidate
) O
and O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
. O

Short-term O
studies O
did O
not O
show O
an O
increase O
in O
the O
risk O
of O
suicidality B-NonOSE_AE
with O
these O
drugs O
compared O
to O
placebo O
in O
adults O
beyond O
age O
24 O
; O
there O
was O
a O
reduction O
in O
suicidality B-NonOSE_AE
risk O
with O
antidepressants O
compared O
to O
placebo O
in O
adults O
age O
65 O
and O
older O
. O

The O
pooled O
analyses O
of O
placebo-controlled O
trials O
in O
children O
and O
adolescents O
with O
MDD B-Not_AE_Candidate
, O
obsessive B-Not_AE_Candidate
compulsive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
( I-Not_AE_Candidate
OCD I-Not_AE_Candidate
) O
, O
or O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
included O
a O
total O
of O
24 O
short-term O
trials O
of O
9 O
drugs O
used O
to O
treat O
depression B-Not_AE_Candidate
in O
over O
4400 O
patients O
. O

The O
pooled O
analyses O
of O
placebo-controlled O
trials O
in O
adults O
with O
MDD B-Not_AE_Candidate
or O
other O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
included O
a O
total O
of O
295 O
short-term O
trials O
( O
median O
duration O
of O
2 O
months O
) O
of O
11 O
antidepressant O
drugs O
in O
over O
77,000 O
patients O
. O

There O
was O
considerable O
variation O
in O
risk O
of O
suicidality B-OSE_Labeled_AE
among O
drugs O
, O
but O
a O
tendency O
toward O
an O
increase O
in O
the O
younger O
patients O
for O
almost O
all O
drugs O
studied O
. O

There O
were O
differences O
in O
absolute O
risk O
of O
suicidality B-NonOSE_AE
across O
the O
different O
indications O
, O
with O
the O
highest O
incidence O
in O
MDD B-Not_AE_Candidate
. O

The O
risk O
of O
differences O
( O
drug O
versus O
placebo O
) O
, O
however O
, O
were O
relatively O
stable O
within O
age O
strata O
and O
across O
indications O
. O

These O
risk O
differences O
( O
drug-placebo O
difference O
in O
the O
number O
of O
cases O
of O
suicidality B-NonOSE_AE
per O
1000 O
patients O
treated O
) O
are O
provided O
in O
Table O
1 O
. O

Table O
1 O
: O
Risk O
Differences O
( O
Drug O
- O
Placebo O
) O
in O
the O
number O
of O
Cases O
of O
Suicidality B-OSE_Labeled_AE
, O
per O
1000 O
patients O
treated O
Age O
Range O
Drug-Placebo O
Difference O
in O
Number O
of O
Cases O
of O
Suicidality O
per O
1000 O
Patients O
Treated O
< O
18 O
14 O
additional O
cases O
18-24 O
5 O
additional O
cases O
Decreases O
Compared O
to O
Placebo O
25-64 O
1 O
fewer O
case O
> O
= O
65 O
6 O
fewer O
cases O
No O
suicides B-NonOSE_AE
occurred O
in O
any O
of O
the O
pediatric O
trials O
. O

There O
were O
suicides B-NonOSE_AE
in O
the O
adult O
trials O
, O
but O
the O
number O
was O
not O
sufficient O
to O
reach O
any O
conclusion O
about O
drug O
effect O
on O
suicide B-NonOSE_AE
. O

It O
is O
unknown O
whether O
the O
suicidality B-NonOSE_AE
risk O
extends O
to O
longer-term O
use O
, O
i.e. O
, O
beyond O
several O
months O
. O

However O
, O
there O
is O
substantial O
evidence O
from O
placebo-controlled O
maintenance O
trials O
in O
adults O
with O
depression B-Not_AE_Candidate
that O
the O
use O
of O
antidepressants O
can O
delay O
the O
recurrence O
of O
depression B-NonOSE_AE
. O

All O
patients O
being O
treated O
with O
drugs O
inhibiting O
the O
reuptake O
of O
norepinephrine O
and/or O
serotonin O
for O
any O
indication O
should O
be O
monitored O
appropriately O
and O
observed O
closely O
for O
clinical O
worsening O
, O
suicidality B-NonOSE_AE
, O
and O
unusual B-NonOSE_AE
changes I-NonOSE_AE
in I-NonOSE_AE
behavior I-NonOSE_AE
, O
especially O
during O
the O
initial O
few O
months O
of O
a O
course O
of O
drug O
therapy O
, O
or O
at O
times O
of O
dose O
changes O
, O
either O
increases O
or O
decreases O
. O

The O
following O
symptoms O
, O
anxiety B-OSE_Labeled_AE
, O
agitation B-OSE_Labeled_AE
, O
panic B-OSE_Labeled_AE
attacks I-OSE_Labeled_AE
, O
insomnia B-OSE_Labeled_AE
, O
irritability B-OSE_Labeled_AE
, O
hostility B-OSE_Labeled_AE
, O
aggressiveness B-OSE_Labeled_AE
, O
impulsivity B-OSE_Labeled_AE
, O
akathisia B-OSE_Labeled_AE
( O
psychomotor B-OSE_Labeled_AE
restlessness I-OSE_Labeled_AE
) O
, O
hypomania B-OSE_Labeled_AE
, O
mania B-OSE_Labeled_AE
, O
have O
been O
reported O
in O
adult O
and O
pediatric O
patients O
being O
treated O
with O
drugs O
inhibiting O
the O
reuptake O
of O
norepinephrine O
and/or O
serotonin O
for O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
as O
well O
as O
for O
other O
indications O
, O
both O
psychiatric B-Not_AE_Candidate
and O
nonpsychiatric O
. O

Although O
a O
causal O
link O
between O
the O
emergence O
of O
such O
symptoms O
and O
either O
the O
worsening B-NonOSE_AE
of I-NonOSE_AE
depression I-NonOSE_AE
and/or O
the O
emergence O
of O
suicidal B-NonOSE_AE
impulses I-NonOSE_AE
has O
not O
been O
established O
, O
there O
is O
concern O
that O
such O
symptoms O
may O
represent O
precursors O
to O
emerging O
suicidality B-NonOSE_AE
. O

Consideration O
should O
be O
given O
to O
changing O
the O
therapeutic O
regimen O
, O
including O
possibly O
discontinuing O
the O
medication O
, O
in O
patients O
who O
may O
experience O
worsening O
depressive B-NonOSE_AE
symptoms I-NonOSE_AE
, O
or O
who O
are O
experiencing O
emergent O
suicidality B-NonOSE_AE
or O
symptoms O
that O
might O
be O
precursors O
to O
worsening O
depression B-NonOSE_AE
or O
suicidality B-NonOSE_AE
, O
especially O
if O
these O
symptoms O
are O
severe O
or O
abrupt O
in O
onset O
, O
or O
were O
not O
part O
of O
the O
patient O
's O
presenting O
symptoms O
. O

If O
the O
decision O
has O
been O
made O
to O
discontinue O
treatment O
due O
to O
worsening O
depressive B-NonOSE_AE
symptoms I-NonOSE_AE
or O
emergent O
suicidality B-NonOSE_AE
, O
medication O
should O
be O
tapered O
, O
as O
rapidly O
as O
is O
feasible O
, O
but O
with O
recognition O
that O
abrupt O
discontinuation O
can O
produce O
withdrawal B-NonOSE_AE
symptoms I-NonOSE_AE
[ O
see O
Dosage O
and O
Administration O
( O
2.1 O
, O
2.4 O
) O
, O
and O
Warnings O
and O
Precautions O
( O
5.7 O
) O
] O
. O

Families O
and O
caregivers O
of O
patients O
being O
treated O
with O
drugs O
inhibiting O
the O
reuptake O
of O
norepinephrine O
and/or O
serotonin O
for O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
or O
other O
indications O
, O
both O
psychiatric O
and O
nonpsychiatric O
, O
should O
be O
alerted O
about O
the O
need O
to O
monitor O
patients O
for O
the O
emergence O
of O
agitation B-NonOSE_AE
, O
irritability B-NonOSE_AE
, O
unusual B-NonOSE_AE
changes I-NonOSE_AE
in I-NonOSE_AE
behavior I-NonOSE_AE
, O
and O
the O
other O
symptoms O
described O
above O
, O
as O
well O
as O
the O
emergence O
of O
suicidality B-NonOSE_AE
, O
and O
to O
report O
such O
symptoms O
immediately O
to O
health O
care O
providers O
. O

Such O
monitoring O
should O
include O
daily O
observation O
by O
families O
and O
caregivers O
. O

Prescriptions O
for O
Savella O
should O
be O
written O
for O
the O
smallest O
quantity O
of O
tablets O
consistent O
with O
good O
patient O
management O
, O
in O
order O
to O
reduce O
the O
risk O
of O
overdose B-NonOSE_AE
. O

5.2 O
Serotonin O
Syndrome O
The O
development O
of O
a O
potentially O
life-threatening O
serotonin B-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
has O
been O
reported O
with O
SNRIs O
and O
SSRIs O
, O
including O
Savella O
, O
alone O
but O
particularly O
with O
concomitant O
use O
of O
other O
serotonergic O
drugs O
( O
including O
triptans O
, O
tricyclic O
antidepressants O
, O
fentanyl O
, O
lithium O
, O
tramadol O
, O
tryptophan O
, O
buspirone O
, O
and O
St O
. O
John O
's O
Wort O
) O
and O
with O
drugs O
that O
impair O
metabolism O
of O
serotonin O
( O
in O
particular O
MAOIs O
, O
both O
those O
intended O
to O
treat O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
and O
also O
others O
, O
such O
as O
linezolid O
and O
intravenous O
methylene O
blue O
) O
. O

Serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
symptoms O
may O
include O
mental B-NonOSE_AE
status I-NonOSE_AE
changes I-NonOSE_AE
( O
e.g. O
, O
agitation B-NonOSE_AE
, O
hallucinations B-NonOSE_AE
, O
delirium B-NonOSE_AE
, O
and O
coma B-NonOSE_AE
) O
, O
autonomic B-NonOSE_AE
instability I-NonOSE_AE
( O
e.g. O
, O
tachycardia B-NonOSE_AE
, O
labile B-NonOSE_AE
blood I-NonOSE_AE
pressure I-NonOSE_AE
, O
dizziness B-NonOSE_AE
, O
diaphoresis B-NonOSE_AE
, O
flushing B-NonOSE_AE
, O
hyperthermia B-NonOSE_AE
) O
, O
neuromuscular B-NonOSE_AE
symptoms I-NonOSE_AE
( O
e.g. O
, O
tremor B-NonOSE_AE
, O
rigidity B-NonOSE_AE
, O
myoclonus B-NonOSE_AE
, O
hyperreflexia B-NonOSE_AE
, O
incoordination B-NonOSE_AE
) O
, O
seizures B-NonOSE_AE
, O
and/or O
gastrointestinal B-NonOSE_AE
symptoms I-NonOSE_AE
( O
e.g. O
, O
nausea B-NonOSE_AE
, O
vomiting B-NonOSE_AE
, O
diarrhea B-NonOSE_AE
) O
. O

Patients O
should O
be O
monitored O
for O
the O
emergence O
of O
serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
. O

The O
concomitant O
use O
of O
Savella O
with O
MAOIs O
intended O
to O
treat O
psychiatric B-Not_AE_Candidate
disorders I-Not_AE_Candidate
is O
contraindicated O
. O

Savella O
should O
also O
not O
be O
started O
in O
a O
patient O
who O
is O
being O
treated O
with O
MAOIs O
such O
as O
linezolid O
or O
intravenous O
methylene O
blue O
. O

All O
reports O
with O
methylene O
blue O
that O
provided O
information O
on O
the O
route O
of O
administration O
involved O
intravenous O
administration O
in O
the O
dose O
range O
of O
1 O
mg/kg O
to O
8 O
mg/kg O
. O

No O
reports O
involved O
the O
administration O
of O
methylene O
blue O
by O
other O
routes O
( O
such O
as O
oral O
tablets O
or O
local O
tissue O
injection O
) O
or O
at O
lower O
doses O
. O

There O
may O
be O
circumstances O
when O
it O
is O
necessary O
to O
initiate O
treatment O
with O
an O
MAOI O
such O
as O
linezolid O
or O
intravenous O
methylene O
blue O
in O
a O
patient O
taking O
Savella O
. O

Savella O
should O
be O
discontinued O
before O
initiating O
treatment O
with O
the O
MAOI O
[ O
see O
Contraindications O
( O
4.1 O
) O
, O
Dosage O
and O
Administration O
( O
2.5 O
, O
2.6 O
) O
] O
. O

If O
concomitant O
use O
of O
Savella O
with O
other O
serotonergic O
drugs O
including O
triptans O
, O
tricyclic O
antidepressants O
, O
fentanyl O
, O
lithium O
, O
tramadol O
, O
buspirone O
, O
tryptophan O
and O
St O
. O
John O
's O
Wort O
is O
clinically O
warranted O
, O
patients O
should O
be O
made O
aware O
of O
a O
potential O
increased O
risk O
for O
serotonin B-NonOSE_AE
syndrome I-NonOSE_AE
, O
particularly O
during O
treatment O
initiation O
and O
dose O
increases O
. O

Treatment O
with O
Savella O
and O
any O
concomitant O
serotonergic O
agents O
should O
be O
discontinued O
immediately O
if O
the O
above O
events O
occur O
, O
and O
supportive O
symptomatic O
treatment O
should O
be O
initiated O
. O

5.3 O
Elevated O
Blood O
Pressure O
A O
double-blind O
, O
placebo-controlled O
ambulatory O
blood O
pressure O
monitoring O
( O
ABPM O
) O
study O
was O
conducted O
to O
evaluate O
the O
effects O
of O
milnacipran O
( O
up O
to O
200 O
mg/day O
) O
on O
blood O
pressure O
in O
321 O
fibromyalgia B-Not_AE_Candidate
patients O
. O

Among O
fibromyalgia B-Not_AE_Candidate
patients O
who O
were O
normotensive O
at O
baseline O
, O
an O
analysis O
of O
the O
blood O
pressure O
findings O
demonstrated O
a O
substantially O
higher O
proportion O
of O
Savella-treated O
patients O
had O
a O
hypertensive B-OSE_Labeled_AE
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
measurement O
at O
the O
Week O
4 O
, O
50 O
mg O
BID O
steady O
state O
visit O
( O
17.7 O
% O
[ O
n=21/119 O
] O
) O
and O
the O
Week O
7 O
, O
100 O
mg O
BID O
steady O
state O
visit O
( O
14.3 O
% O
[ O
n=15/105 O
] O
) O
as O
compared O
to O
placebo-treated O
patients O
( O
3.7 O
% O
[ O
n=2/54 O
] O
and O
0 O
% O
[ O
0/49 O
] O
at O
the O
Week O
4 O
and O
Week O
7 O
visits O
, O
respectively O
) O
. O

Hypertension B-NonOSE_AE
was O
defined O
as O
mean B-NonOSE_AE
systolic I-NonOSE_AE
blood I-NonOSE_AE
pressure I-NonOSE_AE
( O
SBP O
) O
> I-NonOSE_AE
= I-NonOSE_AE
1 I-NonOSE_AE
4 I-NonOSE_AE
0 I-NonOSE_AE
mmHg I-NonOSE_AE
and O
change B-NonOSE_AE
from I-NonOSE_AE
baseline I-NonOSE_AE
in I-NonOSE_AE
mean I-NonOSE_AE
SBP I-NonOSE_AE
> I-NonOSE_AE
= I-NonOSE_AE
1 I-NonOSE_AE
0 I-NonOSE_AE
mmHg I-NonOSE_AE
or O
mean B-NonOSE_AE
diastolic I-NonOSE_AE
blood I-NonOSE_AE
pressure I-NonOSE_AE
( I-NonOSE_AE
DBP I-NonOSE_AE
) I-NonOSE_AE
> I-NonOSE_AE
= I-NonOSE_AE
9 I-NonOSE_AE
0 I-NonOSE_AE
mmHg I-NonOSE_AE
and O
change B-NonOSE_AE
from I-NonOSE_AE
baseline I-NonOSE_AE
in I-NonOSE_AE
mean I-NonOSE_AE
DBP I-NonOSE_AE
> I-NonOSE_AE
= I-NonOSE_AE
5 I-NonOSE_AE
mmHg I-NonOSE_AE
for O
the O
12-hour O
period O
post O
AM O
study O
drug O
measurement O
at O
that O
visit O
. O

Furthermore O
, O
1.9 O
% O
( O
4/210 O
) O
of O
Savella-treated O
and O
0.9 O
% O
( O
1/111 O
) O
of O
placebo O
patients O
discontinued O
treatment O
for O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
. O

The O
increased B-OSE_Labeled_AE
risk I-OSE_Labeled_AE
of I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
measurements O
in O
the O
hypertensive B-OSE_Labeled_AE
range O
in O
Savella-treated O
patients O
is O
supported O
by O
substantial O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
mean I-OSE_Labeled_AE
SBP I-OSE_Labeled_AE
and O
DBP O
measurements O
observed O
in O
the O
ABPM O
study O
. O

Table O
2 O
shows O
that O
, O
following O
treatment O
with O
Savella O
50 O
mg O
BID O
for O
three O
weeks O
in O
patients O
who O
were O
normotensive O
at O
baseline O
, O
the O
mean B-OSE_Labeled_AE
increase I-OSE_Labeled_AE
from I-OSE_Labeled_AE
baseline I-OSE_Labeled_AE
was I-OSE_Labeled_AE
5 I-OSE_Labeled_AE
mmHg I-OSE_Labeled_AE
in I-OSE_Labeled_AE
systolic I-OSE_Labeled_AE
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
( I-OSE_Labeled_AE
SBP I-OSE_Labeled_AE
) O
and O
diastolic O
blood O
pressure O
( O
DBP O
) O
. O

After O
further O
treatment O
with O
Savella O
100 O
mg O
BID O
for O
two O
weeks O
, O
the O
mean B-OSE_Labeled_AE
increase I-OSE_Labeled_AE
from I-OSE_Labeled_AE
baseline I-OSE_Labeled_AE
in I-OSE_Labeled_AE
SBP O
and O
DBP I-OSE_Labeled_AE
was O
6 O
mmHg O
. O

Similar O
elevations O
occurred O
in O
Savella-treated O
patients O
who O
were O
hypertensive B-Not_AE_Candidate
at O
baseline O
. O

Table O
2 O
: O
Mean B-OSE_Labeled_AE
( O
Standard O
Error O
) O
Change I-OSE_Labeled_AE
from O
Baseline O
in O
Mean O
24-hour O
Systolic I-OSE_Labeled_AE
and O
Diastolic O
Blood I-OSE_Labeled_AE
Pressure I-OSE_Labeled_AE
( O
mmHg O
) O
of O
Milnacipran O
or O
Placebo O
following O
4 O
Weeks O
of O
Treatment O
( O
50mg O
BID O
) O
and O
a O
Subsequent O
2 O
Weeks O
of O
Treatment O
( O
100mg O
BID O
) O
*Blood O
pressure O
measurements O
made O
after O
3 O
weeks O
of O
milnacipran O
50mg O
BID O
^Blood O
pressure O
measurements O
made O
after O
2 O
weeks O
of O
milnacipran O
100mg O
BID O
Normotensive O
Hypertensive B-Not_AE_Candidate
n O
Systolic O
Diastolic O
n O
Systolic O
Diastolic O
Placebo O
39 O
0 O
( O
2 O
) O
-1 O
( O
1 O
) O
50 O
0 O
( O
2 O
) O
0 O
( O
2 O
) O
50 O
mg O
BID* O
92 O
5 O
( O
1 O
) O
5 O
( O
1 O
) O
84 O
5 O
( O
2 O
) O
4 O
( O
1 O
) O
Placebo O
37 O
0 O
( O
2 O
) O
-1 O
( O
1 O
) O
47 O
-1 O
( O
2 O
) O
0 O
( O
1 O
) O
100 O
mg O
BID^ O
82 O
6 O
( O
1 O
) O
6 O
( O
1 O
) O
80 O
5 O
( O
2 O
) O
4 O
( O
1 O
) O
Similar O
patterns O
of O
treatment-emergent O
blood B-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
elevations I-OSE_Labeled_AE
were O
observed O
in O
Phase O
3 O
and O
clinical O
pharmacology O
studies O
as O
manifested O
by O
an O
increased O
risk O
of O
new O
onset O
hypertension B-OSE_Labeled_AE
or O
substantial O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
end O
of O
study O
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
measurements O
in O
patients O
with O
hypertension B-Not_AE_Candidate
at O
baseline O
( O
Table O
3 O
) O
. O

Table O
3 O
: O
Blood O
pressure O
changes O
in O
Phase O
3 O
randomized O
controlled O
trials O
Milnacipran50 O
mg O
BID O
Milnacipran100 O
mg O
BID O
Placebo O
FM B-Not_AE_Candidate
patients O
normotensive O
at O
baseline O
who O
became O
hypertensive B-OSE_Labeled_AE
( O
defined O
as O
SBP B-NonOSE_AE
> I-NonOSE_AE
= I-NonOSE_AE
1 I-NonOSE_AE
4 I-NonOSE_AE
0 I-NonOSE_AE
mmHg I-NonOSE_AE
or O
DBP B-NonOSE_AE
> I-NonOSE_AE
= I-NonOSE_AE
9 I-NonOSE_AE
0 I-NonOSE_AE
mmHg I-NonOSE_AE
on O
three O
consecutive O
post-baseline O
visits O
) O
20 O
% O
17 O
% O
7 O
% O
FM B-Not_AE_Candidate
patients O
with O
sustained O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
SBP I-OSE_Labeled_AE
( O
increase O
of O
> O
= O
15 O
mmHg O
on O
three O
consecutive O
post-baseline O
visits O
) O
9 O
% O
6 O
% O
2 O
% O
FM B-Not_AE_Candidate
patients O
with O
sustained O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
DBP I-OSE_Labeled_AE
( O
increase O
of O
> O
= O
10 O
mmHg O
on O
three O
consecutive O
post-baseline O
visits O
) O
13 O
% O
10 O
% O
4 O
% O
FM B-Not_AE_Candidate
patients O
hypertensive B-Not_AE_Candidate
at O
baseline O
who O
had O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
SBP I-OSE_Labeled_AE
> O
= O
15 O
mmHg O
at O
end O
of O
study O
10 O
% O
7 O
% O
4 O
% O
FM B-Not_AE_Candidate
patients O
hypertensive B-Not_AE_Candidate
at O
baseline O
who O
had O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
DBP I-OSE_Labeled_AE
> O
= O
10 O
mmHg O
at O
end O
of O
study O
8 O
% O
6 O
% O
3 O
% O
Sustained O
increases B-NonOSE_AE
in I-NonOSE_AE
blood I-NonOSE_AE
pressure I-NonOSE_AE
may O
have O
adverse O
consequences O
. O

Cases O
of O
elevated B-OSE_Labeled_AE
blood I-OSE_Labeled_AE
pressure I-OSE_Labeled_AE
requiring O
immediate O
treatment O
have O
been O
reported O
. O

Concomitant O
use O
of O
Savella O
with O
drugs O
that O
increase B-NonOSE_AE
blood I-NonOSE_AE
pressure I-NonOSE_AE
and O
heart B-NonOSE_AE
rate I-NonOSE_AE
has O
not O
been O
evaluated O
and O
such O
combinations O
should O
be O
used O
with O
caution O
[ O
see O
Drug O
Interactions O
( O
7 O
) O
] O
. O

Effects O
of O
Savella O
on O
blood O
pressure O
in O
patients O
with O
significant O
hypertension B-Not_AE_Candidate
or O
cardiac B-Not_AE_Candidate
disease I-Not_AE_Candidate
have O
not O
been O
systematically O
evaluated O
. O

Savella O
should O
be O
used O
with O
caution O
in O
these O
patients O
. O

Measure O
blood O
pressure O
prior O
to O
initiating O
treatment O
and O
periodically O
monitor O
blood O
pressure O
throughout O
Savella O
treatment O
. O

Treat O
pre-existing O
hypertension B-Not_AE_Candidate
and O
other B-Not_AE_Candidate
cardiovascular I-Not_AE_Candidate
disease I-Not_AE_Candidate
before O
starting O
therapy O
with O
Savella O
. O

For O
patients O
who O
experience O
a O
sustained O
increase B-NonOSE_AE
in I-NonOSE_AE
blood I-NonOSE_AE
pressure I-NonOSE_AE
while O
receiving O
Savella O
, O
either O
reduce O
the O
dose O
or O
discontinue O
treatment O
with O
Savella O
if O
clinically O
warranted O
. O

5.4 O
Elevated O
Heart O
Rate O
A O
double-blind O
, O
placebo-controlled O
ABPM O
study O
was O
conducted O
to O
evaluate O
the O
effects O
of O
milnacipran O
( O
up O
to O
200 O
mg/day O
) O
on O
blood O
pressure O
in O
321 O
fibromyalgia B-Not_AE_Candidate
patients O
[ O
see O
Warnings O
and O
Precautions O
( O
5.3 O
) O
] O
. O

Information O
on O
heart O
rate O
was O
also O
collected O
. O

Following O
treatment O
with O
Savella O
50mg O
BID O
for O
three O
weeks O
in O
patients O
who O
were O
normotensive O
at O
baseline O
, O
the O
mean O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
mean O
24-hour O
heart I-OSE_Labeled_AE
rate I-OSE_Labeled_AE
from O
baseline O
was O
13 O
beats O
per O
minute O
. O

After O
further O
treatment O
with O
Savella O
100 O
mg O
BID O
for O
two O
weeks O
, O
the O
mean O
increase B-OSE_Labeled_AE
from I-OSE_Labeled_AE
baseline I-OSE_Labeled_AE
in I-OSE_Labeled_AE
heart I-OSE_Labeled_AE
rate I-OSE_Labeled_AE
was O
13 O
beats O
per O
minute O
. O

Similar O
trends O
were O
observed O
in O
the O
clinical O
trials O
where O
Savella O
treatment O
was O
associated O
with O
mean O
increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
heart I-OSE_Labeled_AE
rate I-OSE_Labeled_AE
of O
approximately O
7 O
to O
8 O
beats O
per O
minute O
[ O
see O
Adverse O
Reactions O
( O
6.1 O
] O
. O

Increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
heart I-OSE_Labeled_AE
rate I-OSE_Labeled_AE
> O
= O
20 O
beats O
per O
minute O
occurred O
more O
frequently O
in O
Savella-treated O
patients O
when O
compared O
to O
placebo O
( O
8 O
% O
in O
the O
Savella O
50 O
mg O
BID O
and O
100 O
mg O
BID O
treatment O
arms O
versus O
0.3 O
% O
in O
the O
placebo O
arm O
) O
. O

Savella O
has O
not O
been O
systematically O
evaluated O
in O
patients O
with O
a O
cardiac B-Not_AE_Candidate
rhythm I-Not_AE_Candidate
disorder I-Not_AE_Candidate
. O

Measure O
heart O
rate O
prior O
to O
initiating O
treatment O
and O
periodically O
monitor O
the O
heart O
rate O
throughout O
Savella O
treatment O
. O

Treat O
pre-existing O
tachyarrhythmias B-Not_AE_Candidate
and O
other O
cardiac B-Not_AE_Candidate
disease I-Not_AE_Candidate
before O
starting O
therapy O
with O
Savella O
. O

For O
patients O
who O
experience O
a O
sustained O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
heart I-OSE_Labeled_AE
rate I-OSE_Labeled_AE
while O
receiving O
Savella O
, O
either O
reduce O
the O
dose O
or O
discontinue O
treatment O
with O
Savella O
if O
clinically O
warranted O
. O

5.5 O
Seizures O
Savella O
has O
not O
been O
systematically O
evaluated O
in O
patients O
with O
a O
seizure B-Not_AE_Candidate
disorder I-Not_AE_Candidate
. O

In O
clinical O
trials O
evaluating O
Savella O
in O
patients O
with O
fibromyalgia B-Not_AE_Candidate
, O
seizures B-NonOSE_AE
/ O
convulsions B-NonOSE_AE
have O
not O
been O
reported O
. O

However O
, O
seizures B-NonOSE_AE
have O
been O
reported O
infrequently O
in O
patients O
treated O
with O
Savella O
for O
disorders O
other O
than O
fibromyalgia B-Not_AE_Candidate
. O

Savella O
should O
be O
prescribed O
with O
care O
in O
patients O
with O
a O
history O
of O
a O
seizure B-Not_AE_Candidate
disorder I-Not_AE_Candidate
. O

5.6 O
Hepatotoxicity O
In O
the O
placebo-controlled O
fibromyalgia B-Not_AE_Candidate
trials O
, O
increases O
in O
the O
number O
of O
patients O
treated O
with O
Savella O
with O
mild O
elevations B-OSE_Labeled_AE
of I-OSE_Labeled_AE
ALT I-OSE_Labeled_AE
or O
AST O
( O
1-3 O
times O
the O
upper O
limit O
of O
normal O
, O
ULN O
) O
were O
observed O
. O

Increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
ALT I-OSE_Labeled_AE
were O
more O
frequently O
observed O
in O
the O
patients O
treated O
with O
Savella O
100 O
mg/day O
( O
6 O
% O
) O
and O
Savella O
200 O
mg/day O
( O
7 O
% O
) O
, O
compared O
to O
the O
patients O
treated O
with O
placebo O
( O
3 O
% O
) O
. O

One O
patient O
receiving O
Savella O
100 O
mg/day O
( O
0.2 O
% O
) O
had O
an O
increase B-OSE_Labeled_AE
in I-OSE_Labeled_AE
ALT I-OSE_Labeled_AE
greater O
than O
5 O
times O
the O
upper O
limit O
of O
normal O
but O
did O
not O
exceed O
10 O
times O
the O
upper O
limit O
of O
normal O
. O

Increases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
AST I-OSE_Labeled_AE
were O
more O
frequently O
observed O
in O
the O
patients O
treated O
with O
Savella O
100 O
mg/day O
( O
3 O
% O
) O
and O
Savella O
200 O
mg/day O
( O
5 O
% O
) O
compared O
to O
the O
patients O
treated O
with O
placebo O
( O
2 O
% O
) O
. O

The O
increases B-NonOSE_AE
of I-NonOSE_AE
bilirubin I-NonOSE_AE
observed O
in O
the O
fibromyalgia B-Not_AE_Candidate
clinical O
trials O
were O
not O
clinically O
significant O
. O

No O
case O
met O
the O
criteria O
of O
elevated B-NonOSE_AE
ALT I-NonOSE_AE
> I-NonOSE_AE
3 I-NonOSE_AE
x I-NonOSE_AE
ULN I-NonOSE_AE
and O
associated O
with O
an O
increase B-NonOSE_AE
in I-NonOSE_AE
bilirubin I-NonOSE_AE
> O
= O
2x O
ULN O
. O

There O
have O
been O
cases O
of O
increased B-OSE_Labeled_AE
liver I-OSE_Labeled_AE
enzymes I-OSE_Labeled_AE
and O
reports O
of O
severe B-OSE_Labeled_AE
liver I-OSE_Labeled_AE
injury I-OSE_Labeled_AE
, O
including O
fulminant B-OSE_Labeled_AE
hepatitis I-OSE_Labeled_AE
with O
milnacipran O
from O
foreign O
postmarketing O
experience O
. O

In O
the O
cases O
of O
severe B-OSE_Labeled_AE
liver I-OSE_Labeled_AE
injury I-OSE_Labeled_AE
, O
there O
were O
significant O
underlying O
clinical O
conditions O
and/or O
the O
use O
of O
multiple O
concomitant O
medications O
. O

Because O
of O
underreporting O
, O
it O
is O
impossible O
to O
provide O
an O
accurate O
estimate O
of O
the O
true O
incidence O
of O
these O
reactions O
. O

Savella O
should O
be O
discontinued O
in O
patients O
who O
develop O
jaundice B-NonOSE_AE
or O
other O
evidence O
of O
liver B-NonOSE_AE
dysfunction I-NonOSE_AE
. O

Treatment O
with O
Savella O
should O
not O
be O
resumed O
unless O
another O
cause O
can O
be O
established O
. O

Savella O
should O
ordinarily O
not O
be O
prescribed O
to O
patients O
with O
substantial O
alcohol O
use O
or O
evidence O
of O
chronic B-Not_AE_Candidate
liver I-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

5.7 O
Discontinuation O
of O
Treatment O
with O
Savella O
Withdrawal B-OSE_Labeled_AE
symptoms I-OSE_Labeled_AE
have O
been O
observed O
in O
clinical O
trials O
following O
discontinuation O
of O
milnacipran O
, O
as O
with O
other O
SNRIs O
and O
SSRIs O
. O

During O
marketing O
of O
milnacipran O
, O
and O
other O
SNRIs O
and O
SSRIs O
, O
there O
have O
been O
spontaneous O
reports O
of O
adverse O
events O
indicative O
of O
withdrawal B-OSE_Labeled_AE
and O
physical B-OSE_Labeled_AE
dependence I-OSE_Labeled_AE
occurring O
upon O
discontinuation O
of O
these O
drugs O
, O
particularly O
when O
discontinuation O
is O
abrupt O
. O

The O
adverse O
events O
include O
the O
following O
: O
dysphoric B-NonOSE_AE
mood I-NonOSE_AE
, O
irritability B-NonOSE_AE
, O
agitation B-NonOSE_AE
, O
dizziness B-NonOSE_AE
, O
sensory B-NonOSE_AE
disturbances I-NonOSE_AE
( O
e.g. O
, O
paresthesias B-NonOSE_AE
such O
as O
electric B-NonOSE_AE
shock I-NonOSE_AE
sensations I-NonOSE_AE
) O
, O
anxiety B-NonOSE_AE
, O
confusion B-NonOSE_AE
, O
headache B-NonOSE_AE
, O
lethargy B-NonOSE_AE
, O
emotional B-NonOSE_AE
lability I-NonOSE_AE
, O
insomnia B-NonOSE_AE
, O
hypomania B-NonOSE_AE
, O
tinnitus B-NonOSE_AE
, O
and O
seizures B-NonOSE_AE
. O

Although O
these O
events O
are O
generally O
self-limiting O
, O
some O
have O
been O
reported O
to O
be O
severe O
. O

Patients O
should O
be O
monitored O
for O
these O
symptoms B-NonOSE_AE
when I-NonOSE_AE
discontinuing I-NonOSE_AE
treatment I-NonOSE_AE
with O
Savella O
. O

Savella O
should O
be O
tapered O
and O
not O
abruptly O
discontinued O
after O
extended O
use O
. O

If O
intolerable O
symptoms B-NonOSE_AE
occur I-NonOSE_AE
following I-NonOSE_AE
a I-NonOSE_AE
decrease I-NonOSE_AE
in I-NonOSE_AE
the I-NonOSE_AE
dose I-NonOSE_AE
or I-NonOSE_AE
upon I-NonOSE_AE
discontinuation I-NonOSE_AE
of I-NonOSE_AE
treatment I-NonOSE_AE
, O
then O
resuming O
the O
previously O
prescribed O
dose O
may O
be O
considered O
. O

Subsequently O
, O
the O
physician O
may O
continue O
decreasing O
the O
dose O
but O
at O
a O
more O
gradual O
rate O
[ O
see O
Dosage O
and O
Administration O
( O
2.4 O
) O
] O
. O

5.8 O
Hyponatremia O
Hyponatremia B-OSE_Labeled_AE
may O
occur O
as O
a O
result O
of O
treatment O
with O
SSRIs O
and O
SNRIs O
, O
including O
Savella O
. O

In O
many O
cases O
, O
this O
hyponatremia B-OSE_Labeled_AE
appears O
to O
be O
the O
result O
of O
the O
syndrome B-OSE_Labeled_AE
of I-OSE_Labeled_AE
inappropriate I-OSE_Labeled_AE
antidiuretic I-OSE_Labeled_AE
hormone I-OSE_Labeled_AE
secretion I-OSE_Labeled_AE
( O
SIADH O
) O
. O

Cases O
with O
serum B-OSE_Labeled_AE
sodium I-OSE_Labeled_AE
lower I-OSE_Labeled_AE
than I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
1 I-OSE_Labeled_AE
0 I-OSE_Labeled_AE
mmol I-OSE_Labeled_AE
/ I-OSE_Labeled_AE
L I-OSE_Labeled_AE
have O
been O
reported O
. O

Elderly O
patients O
may O
be O
at O
greater O
risk O
of O
developing O
hyponatremia B-OSE_Labeled_AE
with O
SNRIs O
, O
SSRIs O
, O
or O
Savella O
. O

Also O
, O
patients O
taking O
diuretics O
or O
who O
are O
otherwise O
volume B-Not_AE_Candidate
- I-Not_AE_Candidate
depleted I-Not_AE_Candidate
may O
be O
at O
greater O
risk O
[ O
see O
Geriatric O
Use O
( O
8.5 O
) O
] O
. O

Discontinuation O
of O
Savella O
should O
be O
considered O
in O
patients O
with O
symptomatic O
hyponatremia B-NonOSE_AE
. O

Signs O
and O
symptoms O
of O
hyponatremia B-NonOSE_AE
include O
headache B-NonOSE_AE
, O
difficulty B-NonOSE_AE
concentrating I-NonOSE_AE
, O
memory B-NonOSE_AE
impairment I-NonOSE_AE
, O
confusion B-NonOSE_AE
, O
weakness B-NonOSE_AE
, O
and O
unsteadiness B-NonOSE_AE
, O
which O
may O
lead O
to O
falls B-NonOSE_AE
. O

Signs O
and O
symptoms O
associated O
with O
more O
severe O
and/or O
acute O
cases O
have O
included O
hallucination B-NonOSE_AE
, O
syncope B-NonOSE_AE
, O
seizure B-NonOSE_AE
, O
coma B-NonOSE_AE
, O
respiratory B-NonOSE_AE
arrest I-NonOSE_AE
, O
and O
death B-NonOSE_AE
. O

5.9 O
Abnormal O
Bleeding O
SSRIs O
and O
SNRIs O
, O
including O
Savella O
, O
may O
increase O
the O
risk O
of O
bleeding B-OSE_Labeled_AE
events I-OSE_Labeled_AE
. O

Concomitant O
use O
of O
aspirin O
, O
nonsteroidal O
anti-inflammatory O
drugs O
( O
NSAIDs O
) O
, O
warfarin O
, O
and O
other O
anti-coagulants O
may O
add O
to O
this O
risk O
. O

Case O
reports O
and O
epidemiological O
studies O
( O
case-control O
and O
cohort O
design O
) O
have O
demonstrated O
an O
association O
between O
use O
of O
drugs O
that O
interfere O
with O
serotonin O
reuptake O
and O
the O
occurrence O
of O
gastrointestinal B-OSE_Labeled_AE
bleeding I-OSE_Labeled_AE
. O

Bleeding B-OSE_Labeled_AE
events O
related O
to O
SSRIs O
and O
SNRIs O
use O
have O
ranged O
from O
ecchymoses B-OSE_Labeled_AE
, O
hematomas B-OSE_Labeled_AE
, O
epistaxis B-OSE_Labeled_AE
, O
and O
petechiae B-OSE_Labeled_AE
to O
life-threatening O
hemorrhages I-OSE_Labeled_AE
. O

Patients O
should O
be O
cautioned O
about O
the O
risk O
of O
bleeding B-NonOSE_AE
associated O
with O
the O
concomitant O
use O
of O
Savella O
and O
NSAIDs O
, O
aspirin O
, O
or O
other O
drugs O
that O
affect O
coagulation O
. O

5.10 O
Activation O
of O
Mania O
No O
activation O
of O
mania B-NonOSE_AE
or O
hypomania B-NonOSE_AE
was O
reported O
in O
the O
clinical O
trials O
evaluating O
effects O
of O
Savella O
in O
patients O
with O
fibromyalgia B-Not_AE_Candidate
. O

However O
those O
clinical O
trials O
excluded O
patients O
with O
current O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
episode I-Not_AE_Candidate
. O

Activation O
of O
mania B-NonOSE_AE
and O
hypomania B-NonOSE_AE
have O
been O
reported O
in O
patients O
with O
mood B-Not_AE_Candidate
disorders I-Not_AE_Candidate
who O
were O
treated O
with O
other O
similar O
drugs O
for O
major B-Not_AE_Candidate
depressive I-Not_AE_Candidate
disorder I-Not_AE_Candidate
. O

As O
with O
these O
other O
agents O
, O
Savella O
should O
be O
used O
cautiously O
in O
patients O
with O
a O
history O
of O
mania B-Not_AE_Candidate
. O

5.11 O
Patients O
with O
a O
History O
of O
Dysuria O
Because O
of O
their O
noradrenergic O
effect O
, O
SNRIs O
including O
Savella O
, O
can O
affect O
urethral B-OSE_Labeled_AE
resistance I-OSE_Labeled_AE
and O
micturition O
. O

In O
the O
controlled O
fibromyalgia B-Not_AE_Candidate
trials O
, O
dysuria B-OSE_Labeled_AE
occurred O
more O
frequently O
in O
patients O
treated O
with O
Savella O
( O
1 O
% O
) O
than O
in O
placebo-treated O
patients O
( O
0.5 O
% O
) O
. O

Caution O
is O
advised O
in O
use O
of O
Savella O
in O
patients O
with O
a O
history O
of O
dysuria B-Not_AE_Candidate
, O
notably O
in O
male O
patients O
with O
prostatic B-Not_AE_Candidate
hypertrophy I-Not_AE_Candidate
, O
prostatitis B-Not_AE_Candidate
, O
and O
other O
lower B-Not_AE_Candidate
urinary I-Not_AE_Candidate
tract I-Not_AE_Candidate
obstructive I-Not_AE_Candidate
disorders I-Not_AE_Candidate
. O

Male O
patients O
are O
more O
prone O
to O
genitourinary B-NonOSE_AE
adverse I-NonOSE_AE
effects I-NonOSE_AE
, O
such O
as O
dysuria B-NonOSE_AE
or O
urinary B-NonOSE_AE
retention I-NonOSE_AE
, O
and O
may O
experience O
testicular B-NonOSE_AE
pain I-NonOSE_AE
or O
ejaculation B-NonOSE_AE
disorders I-NonOSE_AE
. O

5.12 O
Angle O
Closure O
Glaucoma O
The O
pupillary B-OSE_Labeled_AE
dilation I-OSE_Labeled_AE
that O
occurs O
following O
use O
of O
SNRI O
drugs O
including O
Savella O
may O
trigger O
an O
angle B-OSE_Labeled_AE
closure I-OSE_Labeled_AE
attack I-OSE_Labeled_AE
in O
a O
patient O
with O
anatomically O
narrow O
angles O
who O
does O
not O
have O
a O
patent O
iridectomy O
. O

5.13 O
Concomitant O
Use O
with O
Alcohol O
In O
clinical O
trials O
, O
more O
patients O
treated O
with O
Savella O
developed O
elevated B-OSE_Labeled_AE
transaminases I-OSE_Labeled_AE
than O
did O
placebo O
treated O
patients O
[ O
see O
Warnings O
and O
Precautions O
( O
5.6 O
) O
] O
. O

Because O
it O
is O
possible O
that O
milnacipran O
may O
aggravate B-OSE_Labeled_AE
pre I-OSE_Labeled_AE
- I-OSE_Labeled_AE
existing I-OSE_Labeled_AE
liver I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
, O
Savella O
should O
not O
be O
prescribed O
to O
patients O
with O
substantial O
alcohol O
use O
or O
evidence O
of O
chronic B-Not_AE_Candidate
liver I-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

